Secondary Logo

Journal Logo

HIV reservoir dynamics in HAART-treated poor immunological responder patients under IL-7 therapy

Logerot, Sandrinea,b,c; Rancez, Magalia,b,c; Charmeteau-de Muylder, Bénédictea,b,c; Figueiredo-Morgado, Suzannea,b,c; Rozlan, Sandrad; Tambussi, Giuseppee; Beq, Stéphanied; Couëdel-Courteille, Annea,b,c,f; Cheynier, Rémia,b,c

doi: 10.1097/QAD.0000000000001752
BASIC SCIENCE: CONCISE COMMUNICATIONS
Free

Objectives: Recombinant Human IL-7 (rhIL-7) therapy allows reconstituting systemic and tissue-associated CD4+ T-cell populations in HIV-infected poor immunological responder (PIR) patients. However, in-vitro studies suggest that the impact of rhIL-7 treatment on HIV-DNA loads in vivo remains questionable.

Design: We assessed the dynamics of circulating HIV-DNA loads in IL-7-treated HIV-infected PIR individuals.

Methods: Forty-one rhIL-7-treated and 16 control participants from the INSPIRE-3 clinical trial were included. Participants received three weekly subcutaneous injections of rhIL-7. HIV-DNA was quantified by nested quantitative PCR in white blood cells sampled at D0, D28 and M3 and expressed as per milliliters and per CD4+ T-cell. Changes in HIV-DNA loads in the CD4+ compartment at M3 were confirmed on sorted CD4+ cells.

Results: Together with rhIL-7-induced T-cell expansion, we observed a significant raise in both infected cell frequencies and counts during the first 28 days of follow-up. During this period, HIV-DNA load per CD4+ T-cell also increased, to a lower extent. Three months post-therapy, both the frequencies and counts of infected cells diminished in blood as compared with D28 but remained significantly higher than before IL-7 therapy. In contrast, infection frequencies strongly diminished within CD4+ cells, reaching slightly but significantly lower levels than at baseline.

Conclusion: rhIL-7 treatment initially drives an expansion of HIV reservoir in PIR patients by D28. This expansion is probably not only because of infected cell proliferation, but also to possible enhanced neoinfection, despite highly active antiretroviral therapy. In contrast, subsequent reduction in HIV-DNA load per CD4+ T-cell argues for partial elimination of infected cells between D28 and M3.

aINSERM, U1016, Institut Cochin

bCNRS, UMR8104

cUniversité Paris Descartes, Sorbonne Paris Cité, Paris

dCytheris S.A., Issy les Moulineaux, France

eInfectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy

fUniversité Paris Diderot, Paris, France.

Correspondence to Rémi Cheynier, PhD, Département Immunité Infection Inflammation, INSERM, U1016, Institut Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France. Tel: +33 1 4051 6541; fax: +33 1 4051 6510; e-mail: remi.cheynier@inserm.fr

Received 7 September, 2017

Revised 19 December, 2017

Accepted 8 January, 2018

Back to Top | Article Outline

Introduction

Controlled viral replication under highly active antiretroviral therapy (HAART) allows restoring circulating CD4+ T-cell counts, leading to major enhancement of life expectancy. However, in 15–30% of HAART-treated individuals, CD4+ T-cell counts fail to reconstitute despite long-term control of viral replication upon effective antiviral treatment [1].

Several mechanisms have been associated to poor immunological responder (PIR) profile, such as residual viral replication [2], poor thymic production [3], naïve T-cell depletion because of X4 virus infection [4], Treg expansion [5,6], or NKP44L overexpression by CD4+ T-cells [7].

Suboptimal CD4+ T-cell restoration has been correlated to increased risk to develop opportunistic infection and to higher mortality, which highlight the need for additional treatments for these individuals [8,9]. Recombinant human IL-7 (rhIL-7) was used in various clinical trials, for its activity on both central and peripheral T-cell homeostasis, in order to help PIR participants reconstituting their CD4+ T-cell compartment [10,11]. These trials allowed to conclude that IL7-based therapy stimulates CD4+ T-cell reconstitution as measured in circulating blood, as a consequence of increased thymic output [12] and enhanced survival and proliferation of both naïve and memory T-cells [10,11,13]. More importantly, rhIL-7 therapy allows reconstituting T-cell populations in gut-associated lymphoid tissue [14], as a consequence of its capacity to stimulate local chemokine expression in tissues [15], as well as homing receptor and integrin expressions by circulating T-cells [15,16]. Neither in PIR-associated trials nor in untreated simian immunodeficiency virus (SIV)-infected macaques was IL-7 therapy followed by any significant enhancement of circulating viral loads [10,11,13,17]. Transient viral replication (blips) was only observed during rhIL-7 therapy in a small proportion of participants and was associated to increased frequency of IFN-γ and/or IL-2 producing CD4+ T-cells [10]. Nevertheless, the applicability of rhIL-7 therapy in HIV-infected individuals remains debated because of its possible effect on viral reservoir size. Indeed, in-vitro studies have associated IL-7 stimulation to viral production by sorted CD4+ T-cells [18] and to sustained permissiveness to cellular infection [19–21]. Furthermore, IL-7 stimulates NF-κB activation and SAMHD1 phosphorylation, possibly leading to reactivation of latent viral reservoirs [22–24]. In the present study, we explored the evolution of HIV reservoir in rhIL-7-treated participants from INSPIRE 3 clinical trial.

Back to Top | Article Outline

Materials and methods

Participants

Forty-one rhIL-7 treated participants and 16 controls from the INSPIRE 3 (CLI-107–14) trial were selected for HIV reservoir analysis according to the availability of blood samples at baseline (D0), D28 and month 3 (M3) following the initiation of rhIL-7 therapy (Table 1). In this trial, treated participants received 3 weekly subcutaneous administrations of rhIL-7 (20 μg/kg of body weight) and were followed up quarterly [25].

Table 1

Table 1

Back to Top | Article Outline

HIV-DNA quantification

Total HIV-DNA was quantified on total white blood cell (WBC) lysates as previously described [26]. Total HIV-DNA, was chosen as the most representative measurement of viral reservoir in chronically infected patients under HAART treatment for more than 1 year [27]. Oligonucleotides specific for conserved regions of both gag and env genes were defined on consensus sequences of either HIV-1 clades A/C for South African participants (A/C-envOUT5′-CATGCCTGTGTACCCACAGA; A/C-envOUT3′- CTCTTCTTCTGCTAGACTG/ACCAT; A/C-gagOUT5′- CAGACAGGAACAGAG/AGAACT; A/C-gagOUT3′-ATTCTGCAGCTTCCTCATTGAT; A/C-envIN5′-AGACCCCAACCCACAAGAA; A/C-envIN3′-ACCAGCTGGGGCACAATAAT; A/C-gagIN5′-ATAGAGGTAAAAGACACCAAGGA; A/C-gagIN3′-GGGTGGCTCCTTCTGATAAT) or HIV-1 clade B for European participants (B-envOUT5′-GCCACACATGCCTGTGTACCCACA; B-envOUT3′-TTTAGAATCGCAAAACCAGCCG; B-gagOUT5′-CCCTTCAGACAGGATCAGAA; B-gagOUT3′-ATTCTGCAGCTTCCTCATTGAT; B-envIN5′-AGACCCCAACCCACAAGAA; B-envIN3′-TGGACAGGCCTGTGTAATGA; B-gagIN5′-TAGAGGTAAAAGACACCAAGGA; B-gagIN3′-ATGTCCCCCCACTGTGTTTA) [28,29]. CD3γ chain was used as housekeeping gene [30]. HIV-DNA concentration was calculated as per milliliters and per CD4+ T-cell using blood cell counts.

Back to Top | Article Outline

CD4+ cell purification

PBMCs sampled at D0 and M3 were stained with an anti-CD4-PerCP-Cy5.5 (clone L200, BD-Biosciences, Le Pont de Claix, France) and CD4+ cell population was sorted on a FACS ARIA III (BD-Biosciences). HIV-DNA load was then quantified on purified CD4+ cells, as described above.

Back to Top | Article Outline

Statistical analysis

Statistical analyses were performed using nonparametric Wilcoxon signed-rank test and Spearman rank-order correlations with Real Statistics using Excel software (http://www.real-statistics.com).

Back to Top | Article Outline

Results

In order to assess the consequences of rhIL-7 based therapy on HIV reservoirs, total HIV-DNA loads were quantified on peripheral blood cells sampled at D28 and M3 following the initiation of rhIL-7 therapy. Quantified on total WBC, HIV-DNA concentration very significantly increased during the first 28 days of rhIL-7 therapy [median = 357 HIV copies/106 WBC (interquartile range, IQR: 105–697) at D28 as compared with 104 (IQR: 50–189) at D0; p < 10−6; Fig. 1a). Despite a substantial decrease between D28 and M3, HIV-DNA copies/106 WBC remained significantly higher, 3 months after the initiation of rhIL-7 therapy (M3) than at baseline, with a median 46% increase as compared with D0 [median = 140 HIV copies/106 WBC (40–317); p < 10−3; Fig. 1a]. Similarly, the concentration of HIV-DNA copies adjusted per milliliters of blood significantly rose at D28 [2876 HIV copies/mL (676–4710); p < 10−7; Fig. 1b] and despite significant reduction during subsequent follow-up, remained higher at M3 than before therapy [819 (245–2042) and 500 (144–1044) HIV copies/mL at M3 and D0, respectively; median increase = 86%; p < 10−4; Fig. 1b]. In contrast, no significant change in HIV-DNA loads was observed in the control group, whether the results were expressed in HIV copies/106 WBC [median = 63 (35–195), 77 (2–277) and 83 (32–135) HIV copies/106 WBC at D0, D28 and M3 respectively; n = 16] or in HIV copies/mL [median = 250 (142–881), 493 (7–1809) and 401 (108–632) HIV copies/mL at D0, D28 and M3, respectively; n = 16].

Fig. 1

Fig. 1

To further assess the impact of rhIL-7 treatment on neoinfection in vivo, we extrapolated HIV-DNA loads to circulating CD4+ T-cell counts in all tested samples. Adjusted to CD4+ T-cell counts, HIV reservoir increased in size during the first month of rhIL-7 therapy [median = 3105 (884–5661) HIV-DNA copies/106 CD4+ T-cell at D28 versus 1910 (601–5130) at D0; p = 0.05; Fig. 1c]. Interestingly, an inverse correlation was observed between changes in CD4+ T-cell counts and HIV-DNA/106 CD4+ T-cells in rhIL-7-treated individuals (r = −0.45; p = 0.003; Fig. 1d), suggesting either that rhIL-7-induced viral replication impairs the reconstitution of CD4+ T-cell compartment or that participants who responded to rhIL-7 treatment by high increases in CD4+ T-cells demonstrated a stronger control of HIV replication than participants poorly responding to rhIL-7 therapy. In contrast to HIV-DNA load measured per WBC or per mL, HIV-DNA load per circulating CD4+ T-cell eventually decreased at M3 in a majority of treated individuals [1645 (310–3146) HIV-DNA copies/106 CD4+ T-cells; median 26% decrease as compared with baseline values; p = 0.01; Fig. 1c]. In the control group, no significant evolution was observed [median = 1238 (600–2105), 2321 (37–7737) and 1537 (387–1710) HIV-DNA/106 CD4+ T-cells at D0, D28 and M3, respectively; n = 16].

In order to confirm this observation, we quantified HIV-DNA in purified CD4+ cells from 19 rhIL-7-treated and 9 control participants sampled at D0 and M3 (Fig. 1e). In this subgroup, measured HIV copies/106 CD4+ cells strongly correlated with calculated values (r = 0.72, p < 10−9), confirming the relevance of our initial calculation to estimate HIV-DNA load in CD4+ cells. Very similar results were observed with a decline in HIV-DNA load in 14 rhIL-7 treated individuals [median = 1615 (753–2327) and 1117 (623–1934) HIV copies/106 CD4+ cells at D0 and M3, respectively; 22% mean decline; p = 0.018; Fig. 1e]. No significant modification of HIV-DNA load was observed in the control group [median = 2447 (632–2760) copies/106 CD4+ cells at D0 as compared with 2284 (738–2467) at M3; 3% mean decline; Fig. 1e].

Back to Top | Article Outline

Discussion

In the INSPIRE 3 clinical trial, enlarged HIV-DNA reservoirs accompanied the massive expansion of T-cell compartments triggered by IL-7 during the first 4 weeks of therapy. This expansion of the HIV reservoir is most likely because of CD4+ T-cell proliferation elicited by the high IL-7 concentrations reached both in plasma and, more importantly, in tissues. Indeed, tissue IL-7 concentrations reached after injection of pharmacological doses of the cytokine are sufficient to locally trigger massive T-cell proliferation [15]. Yet, to increase the frequency of infected CD4+ T-cells, as observed at D28 (Fig. 1c), infected CD4+ T-cells should proliferate more than uninfected ones. However, during the first 4 weeks of therapy, rhIL-7-dependant expansion was greater in naïve CD4+ T-cells than in central and effector memory CD4+ T-cells [25] the latter accounting by far, for most of the infected T-cells [26,31,32]. Moreover, it seems highly improbable that HIV-infected memory cells proliferate or survive more than uninfected cells upon IL-7 stimulation.

Accordingly, the increase in HIV-DNA frequencies within the CD4 compartment observed during the first 4 weeks of rhIL-7 therapy argues against IL-7-dependent cell proliferation being the only factor impacting circulating infected CD4+ T-cell frequencies and suggests increased neoinfection despite antiretroviral treatment. Indeed, IL-7 is known to stimulate HIV transcription as a consequence of NF-κB activation and SAMHD1 phosphorylation [22–24,33], leading to partial reactivation of latent viruses, but fails to reduce the size of the reservoir in vitro[22,33]. This is in line with the increased activation of circulating CD4+ T-cells previously observed during the first 4 days of rhIL-7 therapy [11] and with residual viral replication in tissue of PIR patients [2]. Of note, viral blips were occasionally observed in both INSPIRE 3 and previous trials [10,25,34]. However, in virally suppressed patients, IL-7 alone barely stimulates viral replication in latently infected cells, but enhances residual levels of viral replication in productively infected cells [18,20,35]. Moreover, IL-7-mediated enhancement of both HIV transcription and permissiveness of uninfected cells could lead to increased cell-to-cell virus transmission in lymphoid structures, despite antiretroviral treatment [36]. Indeed, as a direct consequence of local IL-7-dependent chemokines expression, and their activation [15–17], IL-7 therapy may increase local CD4+ T-cell concentration and favor cell-to-cell transmission in lymphoid tissues. However, during the first 28 days of therapy, the observed negative correlation between gain in CD4+ T-cell and gain in HIV-DNA load (per/106 CD4+ T-cell; Fig. 1d) could also be a consequence of greater expansion of the naïve T-cell compartment in participants presenting the strongest response to IL-7, whereas participants with lower response preferentially expand memory compartments. Such a possible dichotomy deserves further investigation.

Three months after rhIL-7 therapy, despite significant decrease in total HIV-DNA loads (per mL and per WBC) as compared with D28, these parameters remained higher than at baseline. In contrast, the frequency of infected cells within the CD4+ compartment not only returned to baseline levels, but also decreased in a majority of participants. During this period, the evolution of HIV-DNA load neither correlated with that of CD4+ or CD8+ T-cell counts nor depended upon initial T-cell counts or HIV-DNA load. Such a decline could be a consequence of either preferential expansion and/or survival of the barely infected naïve CD4+ T-cell population or specific elimination of infected cells. In the INSPIRE 2 clinical trial, naïve T-cell counts strongly declined during this period, whereas memory T-cells plateaued [25], the latter containing most of HIV-infected cells. Similar results were observed on a subgroup of participants from the INSPIRE 3 trial (n = 14; data not shown). These data suggest that the decrease in HIV-DNA load between D28 and M3 was not a consequence of the dilution of infected memory cells in larger amounts of uninfected naïve T-cells. Accordingly, one can reason that rhIL-7 therapy could allow better elimination of HIV-expressing cells through improvement of HIV-specific immunity. Indeed, IL-7 stimulation triggers expression of viral proteins in vitro[35], which should allow their recognition by specific CTLs. However, the impact of such a shock and kill strategy was not detected in immunological responder patients under treatment intensification [37] and remained limited in PIR patients as infected cell frequency only declined by 25% during the 3 months follow-up period in our study. Accordingly, even though IL-7 therapy alone will probably not be efficient in a shock and kill strategy, the effect of its combination with other compounds susceptible to stimulate HIV expression deserves further investigation.

Considering that viral reservoirs constitute the major barrier to HIV eradication and has been associated to virological control after HAART treatment discontinuation [38], understanding the molecular pathways and immunovirological parameters triggered by rhIL-7 treatment is required to apprehend HIV-DNA fluctuations observed in IL-7-treated PIR patients. Furthermore, the impact of rhIL-7 therapy on tissue HIV reservoirs remains to be addressed. Finally, considering the large proportion of defective proviruses in patient's quasispecies, the evolution of replication-competent reservoirs upon IL-7 therapy should be further investigated.

Back to Top | Article Outline

Acknowledgements

This work was carried out in partial fulfillment of S.L.'s PhD thesis at Université Paris Descartes, Paris, France. This work was supported by Inserm-ANRS (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales), ANRT (Association Nationale de la Recherche et de la Technologie), in agreement with Cognate Bioservices and RevImmune Inc, owners of the samples from INSPIRE 3 clinical trial. Inserm, CNRS and Université Paris Descartes also supported this work. Cytheris S.A. (now Revimmune Inc.), Inserm-ANRS and Université Paris Descartes supported S.L.'s PhD thesis. The authors would like to thank Caroline Janot Sardet, Caroline Codron and Anne Gregoire for their help in the management of the project.

Author's Contributions: S.L., M.R., S.R., S.F-M and B.C-d.M. performed the experiments. S.B. and R.C. designed the experiments. S.L., M.R., ACC and R.C. analyzed the data. R.C. wrote the manuscript. G.T. directed the steering committee of the INSPIRE 3 clinical trial. All the authors discussed the results and commented the manuscript.

Back to Top | Article Outline

Conflicts of interest

S.B. and S.R. were employees of Cytheris S.A. (now Revimmune Inc.). S.L.'s PhD thesis was supported, in part, by a CIFRE (Convention Industrielle de Formation par la Recherche) fellowship co-funded by the French government and Cytheris S.A., now Revimmune Inc. Cytheris S.A., now Revimmune Inc., which was developing recombinant human IL-7 as an immune enhancer, partly supported this work. The remaining authors declared no competing financial interests.

Back to Top | Article Outline

References

1. Gazzola L, Tincati C, Bellistrì GM, Monforte Ad, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328–337.
2. Mavigner M, Delobel P, Cazabat M, Dubois M, L’faqihi-Olive FE, Raymond S, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4:e7658.
3. Dion ML, Bordi R, Zeidan J, Asaad R, Boulassel MR, Routy JP< ET-AL>. Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection. Blood 2007; 109:2912–2920.
4. Delobel P, Nugeyre MT, Cazabat M, Sandres-Sauné K, Pasquier C, Cuzin L, et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006; 80:10229–10236.
5. Gaardbo JC, Hartling HJ, Ronit A, Springborg K, Gjerdrum LM, Ralfkiær E. Regulatory T cells in HIV-infected immunological nonresponders are increased in blood but depleted in lymphoid tissue and predict immunological reconstitution. J Acquir Immune Defic Syndr 2014; 66:349–357.
6. Horta A, Nobrega C, Amorim-Machado P, Coutinho-Teixeira V, Barreira-Silva P, Boavida S< ET-AL>. Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells. PLoS One 2013; 8:e57336.
7. Sennepin A, Baychelier F, Guihot A, Nel I, Ho Tsong Fang R, Calin R, et al. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy. AIDS 2013; 27:1857–1866.
8. Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, et al. Patients’ characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 2008; 6:100–107.
9. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012; 2012:670957.
10. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997–1007.
11. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K< ET-AL>. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304–6314.
12. Levy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291–300.
13. Nugeyre MT, Monceaux V, Beq S, Cumont MC, Ho Tsong Fang R, Chêne L, et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J Immunol 2003; 171:4447–4453.
14. Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 2014; 10:e1003890.
15. Beq S, Rozlan S, Gautier D, Parker R, Mersseman V, Schilte C, et al. Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood 2009; 114:816–825.
16. Cimbro R, Vassena L, Arthos J, Cicala C, Kehrl JH, Park C, et al. IL-7 induces expression and activation of integrin alpha4beta7 promoting naive T-cell homing to the intestinal mucosa. Blood 2012; 120:2610–2619.
17. Beq S, Nugeyre MT, Ho Tsong Fang R, Gautier D, Legrand R, Schmitt N, et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol 2006; 176:914–922.
18. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128–137.
19. Ducrey-Rundquist O, Guyader M, Trono D. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol 2002; 76:9103–9111.
20. Loisel-Meyer S, Swainson L, Craveiro M, Oburoglu L, Mongellaz C, Costa C, et al. Glut1-mediated glucose transport regulates HIV infection. Proc Natl Acad Sci U S A 2012; 109:2549–2554.
21. Steffens CM, Managlia EZ, Landay A, Al-Harthi L. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 2002; 99:3310–3318.
22. Coiras M, Bermejo M, Descours B, Mateos E, García-Pérez J, López-Huertas MR, et al. IL-7 induces SAMHD1 phosphorylation in CD4+ T lymphocytes, improving early steps of HIV-1 life cycle. Cell Rep 2016; 14:2100–2107.
23. Chene L, Nugeyre MT, Barré-Sinoussi F, Israël N. High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells. J Virol 1999; 73:2064–2073.
24. Lamberti A, Petrella A, Pascale M, Romano MF, Bisogni R, Vita N, et al. Activation of NF-kappaB/Rel transcription factors in human primary peripheral blood mononuclear cells by interleukin 7. Biol Chem 2004; 385:415–417.
25. Thiebaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, et al. Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy: results of 2 phase II multicenter studies. Clin Infect Dis 2016; 62:1178–1185.
26. Fabre-Mersseman V, Dutrieux J, Louise A, Rozlan S, Lamine A, Parker R< ET-AL>. CD4(+) recent thymic emigrants are infected by HIV in vivo, implication for pathogenesis. AIDS 2011; 25:1153–1162.
27. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411–419.
28. Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksenhendler E, Autran B, Wain-Hobson S. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994; 78:373–387.
29. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc Natl Acad Sci U S A 2000; 97:14566–14571.
30. Poulin JF, Sylvestre M, Champagne P, Dion ML, Kettaf N, Dumont A, et al. Evidence for adequate thymic function but impaired naive T-cell survival following allogenic hematopoietic stem cell transplantation in the absence of chronic graft versus host disease. Blood 2003; 21:21.
31. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B< ET-AL>. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893–900.
32. Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, et al. Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202:1738–1748.
33. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 2011; 7:e1002288.
34. Imamichi H, Degray G, Asmuth DM, Fischl MA, Landay AL, Lederman MM, Sereti I. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. Aids 2011; 25:159–164.
35. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121:4321–4329.
36. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530:51–56.
37. Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, et al. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 2016; 30:221–230.
38. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, et al. SPARTACTrial Investigators. HIV-1 DNA predicts disease progression and posttreatment virological control. Elife 2014; 3:e03821.
Keywords:

HIV-DNA load; HIV-infected patients; HIV reservoir; immunotherapy; interleukin 7; poor immunological responders; shock and kill

Copyright © 2018 Wolters Kluwer Health, Inc.